How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/severe-chronic-obstructive-pulmonary-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Severe chronic obstructive pulmonary disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Severe chronic obstructive pulmonary disease (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Severe chronic obstructive pulmonary disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Daliresp	ROFLUMILAST	Arcutis	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	2011-01-01
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Pulmicort Respules	BUDESONIDE	AstraZeneca K.K.	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01
Daxas	Daxas	AstraZeneca		cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Arcutis · 1 drug in Severe chronic obstructive pulmonary disease
AstraZeneca · 1 drug in Severe chronic obstructive pulmonary disease
AstraZeneca K.K. · 1 drug in Severe chronic obstructive pulmonary disease
Novartis · 1 drug in Severe chronic obstructive pulmonary disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Severe chronic obstructive pulmonary disease:

Cite this brief

Drug Landscape (2026). Severe chronic obstructive pulmonary disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-chronic-obstructive-pulmonary-disease. Accessed 2026-06-10.

Severe chronic obstructive pulmonary disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing